Fate Therapeutics (FATE) Other Accumulated Expenses (2013 - 2026)

Fate Therapeutics (FATE) has 14 years of Other Accumulated Expenses data on file, last reported at $4.0 million in Q1 2026.

• Quarterly Other Accumulated Expenses fell 41.48% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 41.48% YoY) and the FY2025 annual result came in at $4.4 million, down 30.62% from the prior year.
• Other Accumulated Expenses retreated to $4.0 million in Q1 2026, from $4.4 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $19.2 million in Q4 2022 to a low of $3.9 million in Q3 2025.
• A 5-year average of $9.8 million and a median of $8.1 million in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 126.86% — and 2025, when it plunged 63.72%.
• Tracing FATE's Other Accumulated Expenses over 5 years: stood at $19.2 million in 2022, then plunged by 57.66% to $8.1 million in 2023, then declined by 21.67% to $6.4 million in 2024, then sank by 30.62% to $4.4 million in 2025, then dropped by 10.24% to $4.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $4.0 million (Q1 2026), $4.4 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.